Rhamnogalacturonan-I based microcapsules for targeted drug release

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Rhamnogalacturonan-I based microcapsules for targeted drug release. / Svagan, Anna J.; Kusic, Anja; De Gobba, Cristian; Larsen, Flemming Hofmann; Sassene, Philip; Zhou, Qi; Van De Weert, Marco; Mullertz, Anette; Jørgensen, Bodil; Ulvskov, Peter.

In: P L o S One, Vol. 11, No. 12, e0168050, 2016.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Svagan, AJ, Kusic, A, De Gobba, C, Larsen, FH, Sassene, P, Zhou, Q, Van De Weert, M, Mullertz, A, Jørgensen, B & Ulvskov, P 2016, 'Rhamnogalacturonan-I based microcapsules for targeted drug release', P L o S One, vol. 11, no. 12, e0168050. https://doi.org/10.1371/journal.pone.0168050

APA

Svagan, A. J., Kusic, A., De Gobba, C., Larsen, F. H., Sassene, P., Zhou, Q., ... Ulvskov, P. (2016). Rhamnogalacturonan-I based microcapsules for targeted drug release. P L o S One, 11(12), [e0168050]. https://doi.org/10.1371/journal.pone.0168050

Vancouver

Svagan AJ, Kusic A, De Gobba C, Larsen FH, Sassene P, Zhou Q et al. Rhamnogalacturonan-I based microcapsules for targeted drug release. P L o S One. 2016;11(12). e0168050. https://doi.org/10.1371/journal.pone.0168050

Author

Svagan, Anna J. ; Kusic, Anja ; De Gobba, Cristian ; Larsen, Flemming Hofmann ; Sassene, Philip ; Zhou, Qi ; Van De Weert, Marco ; Mullertz, Anette ; Jørgensen, Bodil ; Ulvskov, Peter. / Rhamnogalacturonan-I based microcapsules for targeted drug release. In: P L o S One. 2016 ; Vol. 11, No. 12.

Bibtex

@article{0b48e99370c040d7a21d907c10466b57,
title = "Rhamnogalacturonan-I based microcapsules for targeted drug release",
abstract = "Drug targeting to the colon via the oral administration route for local treatment of e.g. inflammatory bowel disease and colonic cancer has several advantages such as needle-free administration and low infection risk. A new source for delivery is plant-polysaccharide based delivery platforms such as Rhamnogalacturonan-I (RG-I). In the gastro-intestinal tract the RG-I is only degraded by the action of the colonic microflora. For assessment of potential drug delivery properties, RG-I based microcapsules (~1 μm in diameter) were prepared by an interfacial poly-addition reaction. The cross-linked capsules were loaded with a fluorescent dye (model drug). The capsules showed negligible and very little in vitro release when subjected to media simulating gastric and intestinal fluids, respectively. However, upon exposure to a cocktail of commercial RG-I cleaving enzymes, ~ 9 times higher release was observed, demonstrating that the capsules can be opened by enzymatic degradation. The combined results suggest a potential platform for targeted drug delivery in the terminal gastro-intestinal tract.",
author = "Svagan, {Anna J.} and Anja Kusic and {De Gobba}, Cristian and Larsen, {Flemming Hofmann} and Philip Sassene and Qi Zhou and {Van De Weert}, Marco and Anette Mullertz and Bodil J{\o}rgensen and Peter Ulvskov",
year = "2016",
doi = "10.1371/journal.pone.0168050",
language = "English",
volume = "11",
journal = "P L o S One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "12",

}

RIS

TY - JOUR

T1 - Rhamnogalacturonan-I based microcapsules for targeted drug release

AU - Svagan, Anna J.

AU - Kusic, Anja

AU - De Gobba, Cristian

AU - Larsen, Flemming Hofmann

AU - Sassene, Philip

AU - Zhou, Qi

AU - Van De Weert, Marco

AU - Mullertz, Anette

AU - Jørgensen, Bodil

AU - Ulvskov, Peter

PY - 2016

Y1 - 2016

N2 - Drug targeting to the colon via the oral administration route for local treatment of e.g. inflammatory bowel disease and colonic cancer has several advantages such as needle-free administration and low infection risk. A new source for delivery is plant-polysaccharide based delivery platforms such as Rhamnogalacturonan-I (RG-I). In the gastro-intestinal tract the RG-I is only degraded by the action of the colonic microflora. For assessment of potential drug delivery properties, RG-I based microcapsules (~1 μm in diameter) were prepared by an interfacial poly-addition reaction. The cross-linked capsules were loaded with a fluorescent dye (model drug). The capsules showed negligible and very little in vitro release when subjected to media simulating gastric and intestinal fluids, respectively. However, upon exposure to a cocktail of commercial RG-I cleaving enzymes, ~ 9 times higher release was observed, demonstrating that the capsules can be opened by enzymatic degradation. The combined results suggest a potential platform for targeted drug delivery in the terminal gastro-intestinal tract.

AB - Drug targeting to the colon via the oral administration route for local treatment of e.g. inflammatory bowel disease and colonic cancer has several advantages such as needle-free administration and low infection risk. A new source for delivery is plant-polysaccharide based delivery platforms such as Rhamnogalacturonan-I (RG-I). In the gastro-intestinal tract the RG-I is only degraded by the action of the colonic microflora. For assessment of potential drug delivery properties, RG-I based microcapsules (~1 μm in diameter) were prepared by an interfacial poly-addition reaction. The cross-linked capsules were loaded with a fluorescent dye (model drug). The capsules showed negligible and very little in vitro release when subjected to media simulating gastric and intestinal fluids, respectively. However, upon exposure to a cocktail of commercial RG-I cleaving enzymes, ~ 9 times higher release was observed, demonstrating that the capsules can be opened by enzymatic degradation. The combined results suggest a potential platform for targeted drug delivery in the terminal gastro-intestinal tract.

U2 - 10.1371/journal.pone.0168050

DO - 10.1371/journal.pone.0168050

M3 - Journal article

VL - 11

JO - P L o S One

JF - P L o S One

SN - 1932-6203

IS - 12

M1 - e0168050

ER -

ID: 171545859